Compass Therapeutics Q3 net loss widens to $14.3 mln

Compass Therapeutics

05/11/2025 12:37

Overview

Compass Therapeutics reports Q3 net loss of $14.3 mln, increased R&D expenses

Company holds $220 mln in cash, providing runway into 2028

New response observed in CTX-8371 Phase 1 study, no dose-limiting toxicities

Outlook

Compass expects to report OS and PFS data for tovecimig in late Q1 2026

CTX-8371 topline data to be presented in H1 2026

CTX-10726 IND filing planned for Q4 2025

Result Drivers

INCREASED R&D EXPENSES - R&D expenses increased due to manufacturing and IND-enabling costs related to CTX-10726

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$14.25 mln
Q3 Basic EPS
-$0.08
Q3 Income From Operations
-$15.81 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Compass Therapeutics Inc. is $10.00, about 62.1% above its November 4 closing price of $3.79

Press Release: ID:nGNX8Pt6W5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)